EXCLUSIVE: Expect Amarin FAQ Shortly
Traders should expect an FAQ posted to Amarin Corporation plc (ADR) (NASDAQ: AMRN)'s website within an hour, a company spokesperson commented to Benzinga.
Editor's note: The FAQ has been updated and can be viewed here.
Amarin's release is expected to add insight to an earlier announcement on drug data titled, "EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study." The data shows that Vascepa (to lower triglycerides) combined with statins (to lower cholesterol) may reduce coronary heart disease risk.
Shares of Amarin have traded in a large range on Monday morning. The stock made a high of $2.30 and last traded at $2.12, up 4 percent on the day.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.